Mediated cellular delivery of LNA oligonucleotides
The present invention relates to novel modified oligomeric compounds and to methods of making and using such compounds. The invention further relates to methods of enhancing the cellular uptake of oligomeric compounds comprising conjugating a metal chelator to those.
1. A compound of formula I:
OLIGO-L-CHEL (I)
wherein “OLIGO” designates an oligonucleotide composition containing one or two LNA monomers within each three nucleotide segment, “CHEL” is 2,2′:6′,2″-terpyridine, and “L” is a linking moiety.
2. A compound of claim 1 wherein “L” is produced from 6-(4-Monomethoxytritylamino)hexyl-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite.
3. A compound of claim 1 wherein the metal chelator is able to remove free metallic ions from solution by forming complexes.
4. A compound of claim 1 wherein at least one LNA monomer is selected from oxy-LNA or amino-LNA.
5. A compound of claim 1 further comprising one or more labels.
6. A method of synthesizing a compound of formula I
OLIGO-L-CHEL (I)
wherein “OLIGO” designates an oligonucleotide composition containing an LNA monomer at every third nucleotide, “CHEL” is 2,2′:6′,2″-terpyridine, and “L” is a linking moiety, comprising the following steps:
a) coupling said linking moiety with a suitable solid phase protecting group to the 5′-end of an oligonucleotide composition attached to a solid phase at the 3′ end,
b) cleaving off said solid phase protecting group using a suitable reagent,
c) conjugating to said linking moiety 2,2′ :6′,2″-terpyridine, and
d) deprotecting said 3′ end.
7. A method of synthesizing a compound of formula I
OLIGO-L-CHEL (I)
wherein “OLIGO” designates an oligonucleotide composition containing one or two LNA monomers within each three nucleotide segment, “CHEL” is 2,2′:6′,2″-terpyridine, and “L” is a linking moiety, comprising the following steps:
a) attaching said linking moiety to a solid phase, b) synthesizing an oligonucleotide composition comprising said linking moiety, c) deprotecting said oligonucleotide composition from said solid phase, and d) conjugating to said linking moiety 2,2′ :6′,2″-terpyridine.
8. A kit comprising a compound of formula I
OLIGO-L-CHEL (I)
wherein “OLIGO” designates an oligonucleotide composition containing one or two LNA monomers within each three nucleotide segment, “CHEL” is 2,2′:6′,2″-terpyridine, and “L” is a linking moiety for use in diagnostics.
9. A method of synthesizing a compound of formula I
OLIGO-L-CHEL (I)
wherein “OLIGO” designates an oligonucleotide composition containing one or two LNA monomers within each three nucleotide segment, “CHEL” is 2,2′:6,2″-terpyridine, and “L” is a linking moiety, comprising the following steps:
a) coupling said linking moiety with a suitable solid phase protecting group to the 5-end of an oligonucleotide composition attached to a solid phase at the 3′ end,
b) cleaving off said solid phase protecting group using a suitable reagent,
c) conjugating to said linking moiety 2,2′:6′,2″-terpyridine, and
d) deprotecting said 3′ end.
10. A compound of claim 1 with an antisense, silencing or knock-down efficacy.